FTC Says Impax Must Sell 10 Generics After Amneal Deal

By RJ Vogt (April 27, 2018, 9:11 PM EDT) -- Six months after generics giant Impax Laboratories Inc. agreed to combine with privately held Amneal Pharmaceuticals LLC, the Federal Trade Commission announced Friday that it is requiring Impax to divest rights and assets for 10 products as part of a settlement over anti-competitive charges....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!